Literature DB >> 15001114

Treatment of patent ductus arteriosus.

Jonathan Wyllie1.   

Abstract

Patent ductus arteriosus (PDA) continues to be one of the most common problems found in premature infants. The incidence is inversely related to gestation, but may be reduced by use of antenatal steroids, lower volume fluid regimen and judicious use of phototherapy. However, there continues to be controversy as to the appropriate indications for treatment, varying from prophylaxis on the basis of gestation to treatment only when a PDA is demonstrably significant. The situation is further complicated by differing diagnostic criteria for ductal patency or significance. Prophylactic treatment is likely to result in up to 64% of babies being treated unnecessarily. Early treatment of significant or symptomatic PDA depends upon accurate diagnosis. PDA closure can then be achieved using medical means, with surgery reserved for patients in whom this fails or in whom there are contra-indications. However, the optimum timing for intervention remains unknown.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15001114     DOI: 10.1016/S1084-2756(03)00121-0

Source DB:  PubMed          Journal:  Semin Neonatol        ISSN: 1084-2756


  16 in total

Review 1.  Managing the baby with a patent ductus arteriosus. More questions than answers?

Authors:  P W Fowlie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05       Impact factor: 5.747

2.  Conservative treatment for patent ductus arteriosus in the preterm.

Authors:  Sophie Vanhaesebrouck; Inge Zonnenberg; Piet Vandervoort; Els Bruneel; Marie-Rose Van Hoestenberghe; Claire Theyskens
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-01-09       Impact factor: 5.747

3.  Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus.

Authors:  Grace Poon
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-01

4.  Patent ductus arteriosus: an overview.

Authors:  James E Dice; Jatinder Bhatia
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

5.  Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre.

Authors:  Gregory P Moore; Sarah L Lawrence; Gyaandeo Maharajh; Amanda Sumner; Isabelle Gaboury; Nick Barrowman; Brigitte Lemyre
Journal:  Paediatr Child Health       Date:  2012-04       Impact factor: 2.253

6.  Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus.

Authors:  Carlo Bellini; Francesco Campone; Giovanni Serra
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

7.  Change in blood pressure and pulse pressure in preterm infants after treatment of patent ductus arteriosus with indomethacin.

Authors:  Ui Joung Han; Hwa Jin Cho; Young Kuk Cho; Young Youn Choi; Jae Sook Ma
Journal:  Korean Circ J       Date:  2011-04-30       Impact factor: 3.243

8.  Genetic contribution to patent ductus arteriosus in the premature newborn.

Authors:  Vineet Bhandari; Gongfu Zhou; Matthew J Bizzarro; Catalin Buhimschi; Naveed Hussain; Jeffrey R Gruen; Heping Zhang
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

9.  Transcatheter closure of patent ductus arteriosus: Evaluating the effect of the learning curve on the outcome.

Authors:  Ahmad S Azhar; Ayman A Abd El-Azim; Hamed S Habib
Journal:  Ann Pediatr Cardiol       Date:  2009-01

10.  The impact of a dedicated patent ductus arteriosus ligation team on neonatal health-care outcomes.

Authors:  M H F Resende; K More; D Nicholls; J Ting; A Jain; P J McNamara
Journal:  J Perinatol       Date:  2016-01-14       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.